Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan.
Department of Genetics, Research Institute of Environmental Medicine Nagoya University, Furo-cho, Chikusa-ku, 464-8601, Nagoya, Japan.
BMC Infect Dis. 2022 Jun 22;22(1):568. doi: 10.1186/s12879-022-07537-6.
Congenital human cytomegalovirus (cCMV) infection can cause sensorineural hearing loss and neurodevelopmental disabilities in children. Ganciclovir and valganciclovir (GCV/VGCV) improve long-term audiologic and neurodevelopmental outcomes for patients with cCMV infection; however, antiviral drug resistance has been documented in some cases. Long-read sequencing can be used for the detection of drug resistance mutations. The objective of this study was to develop full-length analysis of UL97 and UL54, target genes with mutations that confer GCV/VGCV resistance using long-read sequencing, and investigate drug resistance mutation in patients with cCMV infection.
Drug resistance mutation analysis was retrospectively performed in 11 patients with cCMV infection treated with GCV/VGCV. UL97 and UL54 genes were amplified using blood DNA. The amplicons were sequenced using a long-read sequencer and aligned with the reference gene. Single nucleotide variants were detected and replaced with the reference sequence. The replaced sequence was submitted to a mutation resistance analyzer, which is an open platform for drug resistance mutations.
Two drug resistance mutations (UL54 V823A and UL97 A594V) were found in one patient. Both mutations emerged after 6 months of therapy, where viral load increased. Mutation rates subsided after cessation of GCV/VGCV treatment.
Antiviral drug resistance can emerge in patients with cCMV receiving long-term therapy. Full-length analysis of UL97 and UL54 via long-read sequencing enabled the rapid and comprehensive detection of drug resistance mutations.
先天性人巨细胞病毒(cCMV)感染可导致儿童感音神经性听力损失和神经发育障碍。更昔洛韦和缬更昔洛韦(GCV/VGCV)可改善 cCMV 感染患者的长期听力和神经发育结局;然而,在一些病例中已记录到抗病毒药物耐药性。长读测序可用于检测耐药突变。本研究旨在通过长读测序对 UL97 和 UL54 全长分析,检测与 GCV/VGCV 耐药相关的突变,调查 cCMV 感染患者的耐药突变情况。
回顾性分析 11 例接受 GCV/VGCV 治疗的 cCMV 感染患者的耐药突变分析。采用血液 DNA 扩增 UL97 和 UL54 基因。使用长读测序仪对扩增子进行测序,并与参考基因进行比对。检测单核苷酸变异并替换为参考序列。替换序列提交给突变耐药性分析器,这是一个开放的耐药突变分析平台。
在一名患者中发现了两种耐药突变(UL54 V823A 和 UL97 A594V)。这两种突变均出现在治疗 6 个月后病毒载量增加时。停止 GCV/VGCV 治疗后,突变率下降。
接受长期治疗的 cCMV 患者可能会出现抗病毒药物耐药性。通过长读测序对 UL97 和 UL54 进行全长分析可快速全面地检测耐药突变。